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Abstract
Background: Endothelial progenitor cells (EPCs) mediate vascular repair and regeneration. Their number in peripheral blood
is related to cardiovascular events in individuals with normal renal function.
Methods: Weevaluated the associationbetween functionally activeEPCs(cellculture) and traditionalcardiovascularrisk factors
in 265 patients with chronic kidney disease stage V receiving hemodialysis therapy. Thereafter, we prospectively assessed
cardiovascular events, e.g. myocardial infarction, percutaneous transluminal coronary angioplasty (including stenting), aorto-
coronary bypass, stroke and angiographically verified stenosis of peripheral arteries, and cardiovascular death in this cohort.
Results: In our patients EPCs were related only to age (r=0.154; p=0.01). During a median follow-up period of 36 months
109 (41%) patients experienced a cardiovascular event. In a multiple Cox regression analysis, we identified EPCs (p=0.03)
and patient age (p=0.01) as the only independent variables associated with incident cardiovascular events. Moreover, a
total of 70 patients died during follow-up, 45 of those due to cardiovascular causes. Log rank test confirmed statistical
significance for EPCs concerning incident cardiovascular events (p=0.02).
Conclusions: We found a significant association between the number of functionally active EPCs and cardiovascular events
in patients with chronic kidney disease. Thus, defective vascular repair and regeneration may be responsible, at least in part,
for the enormous cardiovascular morbidity in this population.
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Introduction
Endothelial progenitor cells (EPCs) mediate reparative processes
in the cardiovascular (CV) system [1,2]. They originate, at least in
part, from bone-marrow related CD34+ hematopoetic stem cells
and circulate in the vasculature where they home and incorporate
into sites of active neo-vascularization. The existence of EPC
niches outside the bone-marrow has been proposed [3]. In the
general population as well as in patients with coronary artery
disease the number of EPCs correlates significantly with traditional
CV risk factors such as blood pressure [4,5]. Moreover, Hill et al.
[4] could demonstrate that the number of EPCs was a better
predictor of the non-invasively assessed endothelial function in
healthy men than the combined Framingham risk score. Above
that, prospective studies revealed that reduced EPC numbers are a
significant independent predictor of future CV events (CVE) and
of poor prognosis, even after adjustment for traditional CV risk
factors [6,7].
We and others have shown that the number and function of
EPCs is reduced in uremic patients with advanced kidney failure
before treatment of renal anemia with erythropoietin [8–12].
Attenuation of uremic intoxication by hemodialysis (HD) or kidney
transplantation increases EPC numbers and improves their
function [8,11,12]. Since patients with chronic kidney disease
(CKD) represent a high risk population with regard to CVE
[13,14], we set out to explore if EPC numbers correlate with
traditional CV risk factors in a cohort of 265 stable CKD stage V
patients on maintenance HD. Moreover, we studied the
association between EPCs and incident CVE as well as survival
during a prospective follow-up.
Results
We completed a total of 265 data sets from CKD patients on
maintenance HD. Patient characteristics are shown in Table 1.I n
this baseline cohort we found a significant correlation between
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CV risk factors such as hsCRP, total serum cholesterol or blood
pressure. A total of 231 patients received rHuEPO (87%) and 150
patients were on statins (57%). Patients on rHuEPO treatment had
comparable EPCs as those without (419618 vs. 461642 per high
power field; p=0.4). Similarly, we found no significant difference
in EPCs in CKD patients on statins compared to those without
statin therapy (421621 vs. 433627 per high power field; p=0.7).
There was no association between rHuEPO (p=0.287) and statin
(p=0.594) treatment and EPCs.
During the median follow-up period of 36 [1–54] months 109
(41%) patients experienced a CVE. Forty-five patients experienced
a myocardial infarction (17%), 13 patients a stroke (5%), 48
patients underwent a percutaneous transluminal coronary angi-
ography (18%), 5 patients a coronary bypass surgery (2%) and 51
patients showed an angiographically verified stenosis of peripheral
arteries (19%). In addition, a total of 70 patients died during the
follow-up period, 45 of those due to a confirmed CV cause. In that
group 25 patients died due to a myocardial infarction (9%), 10
patients due to a stroke (4%), 10 in the course of a bypass surgery
(4%). Moreover, 17 patients died due to sepsis (6%), 1 due to
Creutzfeld-Jacob disease (0.4%), 1 due to a metastasized protaste
cancer (0.4%), 1 due to a car accident (0.4%), 2 due to pneumonia
(0.8%), 3 in the nursing home (cause of death not known) (1.1%).
In a multiple Cox-regression analysis performed with CV risk
factors listed in Table 2, we identified EPCs (p=0.03) and age
(p=0.01) as the only independent variables associated with
incident CVE, whereas HSCs were not associated with incident
CVE. We performed a ROC-curve analysis (AUC 0.6, 96% CI
0.5–0.64, p=0.03) to determine a cut-off value, which separates
patients with and without incident CVE with respect to EPCs.
Clinical characteristics of patients above and below the cut-off
value are shown in Table 3. A cut-off value of 332 cells per high
power field separated patients with and without incident CVE
with a sensitivity of 61% and a specificity of 53%. Using log rank
testing we could confirm statistical significance for EPCs with
respect to incident CVE stratified to values above and below this
cut-point (p=0.02) (Figure 1). In contrast, EPCs were not
predictive for patient survival (p=0.12). HSCs were not predictive
for incident CVE (p=0.6) and patient survival (p=0.4).
Discussion
In the present study we found a significant relationship between
the number of EPCs and incident CVE in 265 stable patients with
CKD stage V on maintenance HD in a prospective follow-up
period of a median of 36 months. Moreover, in a stepwise logistic
regression analysis including traditional CV risk factors EPCs were
the only independent variable associated with incident CVE. In
contrast, HSCs (assessed by flow cytometry) were not associated
with CVE and patient survival in the follow-up, highlighting the
potential role of EPCs, i.e. cells that are committed to the
Table 1. Clinical and laboratory data of renal patients with and without incident cardiovascular events (CVE) during follow-up.
All patients Incident CVE No CVE p-value
Number 265 109 156
Age (years) 66 (15) 70 (12) 66 (19) 0.02*
Male / female 147/118 64/45 83/73 0.37
Body mass index (kg/m
2) 25.2 (5.8) 25.2 (5.9) 25.5 (5.6) 0.75
Dialysis vintage prior inclusion (months) 39 (68) 38 (51) 39 (73) 0.98
Diabetes (n) 91 40 51 0.5
Peripheral artery disease (n) 95 48 47 0.02*
Coronary artery disease (n) 129 65 64 0.02*
Hypertension (n) 217 90 127 0.69
Patients on statins (n) 150 70 80 0.07
Patients on AT1-antagonists 59 26 33 0.56
Patients on ACE-inhibitors 77 45 32 0.92
Patients on Beta-blockers 86 43 43 0.12
Patients on Calcium-channel-blockers 45 25 20 0.49
Patients on EPO 231 95 136 0.85
EPO-dose (IU/week) 6000 (6000) 6000 (4000) 6000 (5000) 0.18
Current smoker (n) 26 12 14 0.58
MAP (mmHg) 97 (14) 97 (18) 97 (13) 0.94
High sensitivity C-reactive protein (mg/L) 3.9 (6.9) 3.2 (6.2) 4.3 (7) 0.80
Serum total cholesterol (mg/dL) 172 (2.6) 176 (4.3) 168 (3.2) 0.22
Serum triglycerides (mg/dL) 169 (132) 188 (166) 158 (116) 0.56
Serum albumin (g/L) 40 (5) 40 (6) 39 (5) 0.83
EPCs(per high power field) 360 (338) 329 (256) 397 (403) 0.02*
HSCs (per ml) 1.4 (1.11) 1.5 (0.96) 1.4 (1.34) 0.39
MAP = mean arterial blood pressure; EPCs = endothelial progenitor cells; HSCs = CD34+ hematopoetic stem cells. Except for serum total cholesterol levels data are
displayed as median (interquartile range); *p,0.05
doi:10.1371/journal.pone.0011477.t001
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patients. To our knowledge, this is the first study to show such a
relationship in CKD patients after reports in CV high risk patients
with normal kidney function [6,7]. However, in contrast to
individuals with normal kidney function we could find a significant
but only weak correlation between EPCs and age, but not with
other traditional CV risks factors such as high blood pressure or
total serum cholesterol, and with CV risk factors present only in
HD patients such as reduced nutritional status, e.g. low body mass
index and/or serum albumin, and presence of (micro)inflamma-
tion, e.g. increased hsCRP. The latter finding is of particular
important, since it supports the notion that EPCs obtained by
labor intensive and time consuming cell culture methodology, thus
exhibiting several functional properties of endothelial cells, are
indeed related to vascular biology, and are not monocytic cells that
may also be involved in inflammation.
Due to their endothelial and hence vascular repair potential
EPCs have come into focus of CV research in the last decade. This
has been shown in several experimental studies using different
animal models of CV injury [1–3]. In humans, it has been shown
that the number of circulating EPCs correlates with non-invasively
assessed endothelial function [4], and with the number of CV risk
factors in individuals with and without manifest CV disease [4,5].
Hill et al. [4] found a significant negative correlation between EPC
number and the Framingham risk factor score, i.e. a crude
estimate of the risk of coronary artery disease, in asymptomatic
men with established CV risk factors. It has been therefore
hypothesized that traditional CV risk factors such as high blood
pressure and serum cholesterol may impair EPC number and
consequently their regenerative potential [15]. Moreover, a low
CD34+ hematopoetic cell count was associated with CVE and CV
death, independently of all potential confounders, in patients with
metabolic syndrome [16]. Since CKD patients are characterized
by high CV morbidity and mortality due to vascular complica-
tions, their survival could also be influenced, at least in part, by
deficient vascular repair as a result of reduced EPC number and/
or function [8,11,17]. This idea is supported by data of the present
study.
Similar to us Steiner et al. [18] did not find an association
between rHuEPO treatment and EPCs. This observation is of
interest, since we and others could convincingly demonstrate that
administration of rHuEPO is a strong stimulus for EPC
mobilization and proliferation in-vitro and in-vivo [9,19,20].
However, the dose necessary for significant stimulation of EPC
proliferation is much lower than that used for correction of anemia
in CKD patients [9]. Thus, one could speculate that patients who
do not need rHuEPO therapy despite kidney failure, still may have
enough endogenous EPO production to maintain normal EPC
numbers. In line with this speculation is the observation that
patients after successful kidney transplantation have apparently
normal EPC numbers and function [12,21]. Other drugs beside
rHuEPO are known to influence proliferation and differentiation
of EPCs as well, e.g. statins [22] and angiotensin receptor blockers
[23]. Again, we could not find differences in EPCs between
patients treated with statins and those who did not receive these
drugs. We therefore assume that other (unknown?) factors override
the effect of rHuEPO and statins on EPCs in this population.
As a matter of fact, an important confounding factor may be the
dialysis procedure by itself [8,11]. Recent experimental studies
revealed that EPCs represent a heterogeneous cell population of
multiple origins and distinct phenotypes, but share the ability to
differentiate into mature functionally competent endothelial cells
[2,3]. The prevailing view is that a small fraction of bone marrow
derived CD34+ hematopoetic cells are the major source of EPCs,
but EPCs can be also cultured from a CD14+ monocyte/
macrophage population capable of secreting different cytokines
and growth factors [3,24,25]. Thus, the dialysis procedure -
particularly the blood-membrane contact - in combination with
the (micro)inflammatory condition present in many CKD patients
receiving HD may influence the biology (and number?) of this cell
Table 2. Simple and multiple Cox-Regression analysis concerning incident cardiovascular events (CVE) during follow-up.
Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value
Age (years) 1.018 1.003 to 1.034 0.02* 1.021 1.005 to 1.037 0.01*
EPCs (per high power field) 0.999 0.998 to 1.000 0.04* 0.999 0.998 to 1.000 0.03*
Serum Cholesterol (mg/dL) 1.005 1.000 to 1.009 0.05* 1.004 0.999 to 1.008 0.12
Sex (male/female) 1.165 0.795 to 1.705 0.43
Body mass index (kg/m
2) 1.002 0.965 to 1.041 0.91
Dialysis vintage (months) 1 0.998 to 1.003 0.8
Diabetes 1.179 0.799 to 1.740 0.41
Current smoker 0.975 0.523 to 1.819 0.94
MAP (mmHg) 0.999 0.988 to 1.011 0.93
hsC-RP (mg/L) 1.005 0.992 to 1.018 0.45
Triglycerides (mg/dL) 1.001 1.000 to 1.002 0.22
Serum albumin (g/L) 0.992 0.949 to 1.038 0.73
HSCs (per ml) 0.939 0.803 to 1.099 0.43
EPCs = endothelial progenitor cells;
HSCs = CD34+ hematopoetic stem cells;
MAP = mean arterial blood pressure;
hsC-RP = high-sensitive C-reactive protein;
HR = hazard ratio;
CI = confidence interval. *p,0.05
doi:10.1371/journal.pone.0011477.t002
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monocytes [26]. Thus, we have studied EPCs in our patients after
the long HD interval in order to minimize this potential
confounding factor. As another limitation to our study we did
not use the current state-of-the-art detection of EPCs including
CD133, since this flow cytometry surface marker was not part of
the standard panel for detection of EPCs when the study was
initiated.
In conclusion, we found a significant relationship between EPCs
and incident CVE as well as patient survival in stable CKD
patients receiving HD therapy. Thus, our data support a role for
EPCs in vascular repair in CKD patients. Future studies including
patients at earlier stages of CKD are warranted to further
elucidate the role of EPCs in chronic kidney disease.
Methods
Participants and protocol
The study protocol was approved by the Hannover Medical
School Ethics Committee, and we conducted the study in
adherence to the Declaration of Helsinki. We studied stable
Caucasian patients with terminal renal failure from 6 HD centers
in the region of Hannover, Germany. In order to avoid inter-
observer bias all patients data were checked by two independent
subjects who visited all participating centers. All patients gave their
written informed consent for participation.
The study subjects were enrolled between October 2004 and
January 2006. All patients studied were clinically stable and on
maintenance HD for at least 3 months. Patients with concomitant
acute inflammatory diseases, i.e. a high sensitivity C-reactive
protein (hsCRP) above 20 mg/L, or clinically manifest acute
infections, malignant diseases, manifest or occult bleeding
conditions or recent CVE within 3 months prior to enrollment
were excluded from the study. Patient history including dialysis
vintage, co-morbidities, smoking habits, treatment with statins or
recombinant human erythropoietin (rHuEPO) were recorded and
confirmed by checking patients’ records. The medical history was
complemented by a physical examination including assessment of
body mass index (BMI) and resting blood pressure prior to the
start of the HD session. Arterial hypertension was defined as blood
pressure above 140/90 mmHg or antihypertensive treatment.
EDTA blood samples for blood count, routine chemistry, EPC
culture and flow cytometry (FACS-analysis) were drawn from the
dialysis cannulas immediately before the HD session was started.
We carried out these investigations in all patients after a two day
dialysis-free interval (long interval). Part of the blood samples was
used immediately for EPC culture and FACS-analysis; the rest was
centrifuged at 15006ga t4 uC for 10 minutes and then stored at
280uC for further analysis. All routine laboratory measurements
including hsCRP were done using certified assay methods.
After the initial screening, all patients entered a prospective
follow-up (median of 36 [1–54] months). In this period we assessed
all CVE defined as myocardial infarction, percutaneous translu-
minal coronary angioplasty (including stenting), aorto-coronary
bypass, stroke and angiographically verified stenosis of peripheral
arterial vessels (carotic, aorto-iliac or femoral arteries). Further-
more, we also assessed death to any cause including CV death.
Isolation of EPCs
We isolated peripheral blood mononuclear cells from 14 ml
blood in order to cultivate EPCs described in detail previously
Table 3. Clinical and laboratory data of renal patients with
low vs. high levels of endothelial progenitor cells (EPCs)
(above and below 332 EPCs per high power field).
EPC ,332 EPC ,332 p-value
Age (years) 66 (19) 67 (14) 0.29
Male / female 68/53 79/65 0.83
Body mass index (kg/m
2) 25.7 (6) 25.2 (5.3) 0.65
Dialysis vintage prior inclusion
(months)
44 (78) 34 (46) 0.05*
Diabetes (n) 36 55 0.15
Peripheral artery disease (n) 51 44 0.04*
Coronary artery disease (n) 56 73 0.51
Hypertension (n) 102 115 0.28
Patients on statins (n) 78 72 0.04*
Patients on AT1-antagonists 32 27 0.12
Patients on ACE-inhibitors 33 44 0.07




Patients on EPO 106 125 0.71
EPO-dose (IU/week) 6000 (5000) 7000 (5500) 0.01*
Current smoker (n) 6 20 0.02*
MAP (mmHg) 93 (18) 97 (14) 0.47
High sensitivity C-reactive
protein (mg/L)
3.3 (6.2) 3.8 (7.1) 0.69
Serum total cholesterol (mg/dL) 176 (3.9) 168 (3.5) 0.10
Serum triglycerides (mg/dL) 186 (152) 164 (124) 0.09
Serum albumin (g/L) 40 (4) 40 (5) 0.26
EPCs(per high power field) 238 (130) 514 (379) ,0.0001*
HSCs (per ml) 1.4 (1.1) 1.4 (1.0) 0.96
Time to first CVE (months) 33 (40) 37 (36) 0.10
HSCs = CD34+ hematopoetic stem cells. Except for serum total cholesterol
levels data are displayed as median (interquartile range);
*p,0.05
doi:10.1371/journal.pone.0011477.t003
Figure 1. Kaplan-Meier curves for incident CVE in 265 stable
patients with chronic kidney disease stage V receiving
maintenance hemodialysis. Patients were compared above and
below a cut-point of EPC numbers identified by ROC-curve analysis. In
the follow-up period of 36 [1–54] months 109 patients experienced a
CVE. Log rank testing confirmed statistical significance for EPCs with
respect to incident CVE (p=0.02).
doi:10.1371/journal.pone.0011477.g001
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(Biochrome), and seeded 107 cells on 6-well plates coated with
human fibronectin (Sigma) in endothelial basal medium (EBM-2,
Clonetics). The medium was supplemented with EGM-2 Single
Quots containing fetal bovine serum, human VEGF-A, human
fibroblast growth factor-B, human epidermal growth factor,
insulin-like growth factor-1 and ascorbic acid in appropriate
amounts. After 4 days in culture, we removed non-adherent cells
by washing the plates with PBS. We trypsinated the remaining
adherent cells and reseeded 106 cells on fibronectin coated 6-well
plates. New media was applied and the cell culture was maintained
through day 7. We further performed fluorescent chemical
detection in order to determine the cell type of the attached
human peripheral blood mononuclear cells after 7 days in culture.
To detect the uptake of 1,19-dioctadecyl-3,3,39,39-tetramethylin-
docarbocyanine-labeled acetylated low density lipoprotein
(acLDL-DiI, Molecular Probes), we incubated the cells with
acLDL-DiI (6 mg/ml) at 37uC for 2 hours. Cells were then fixed
with 1% para-formaldehyde for 10 minutes and incubated with
FITC-labeled Ulex europaeus agglutinin-1 (UEA-1, Sigma) for
1 hour. After the staining, we viewed the samples with an inverted
fluorescent microscope (Leica). We counted double stained cells
for both UEA-1 and acLDL-DiI as EPCs. Two blinded
investigators counted at least four randomly selected high-power
fields.
Flow cytometry of circulating hematopoetic stem cells
In all patients we analyzed the total number of circulating
CD34+ hematopoetic stem cells (HSCs) using flow cytometry
(Epics XL cytometer, Coulter Beckman). We adopted a gating
strategy for flow cytometry on the basis of the ISHAGE guidelines,
and used the CD34 and CD45 expression patterns as well as the
morphological qualities of progenitor cells for their detection, as
described in detail previously [9]. In brief, we stained whole
EDTA blood within 6 hours after drawing the blood. Thereafter
we incubated a volume of 100 ml with an appropriate amount of
FITC-labeled monoclonal mouse anti-human-CD45 antibody
(Coulter Beckman) for 20 minutes. For detection of HSCs we
added PE-labeled monoclonal mouse anti-human-CD34 antibody
(Coulter Beckman) to the sample after titration of the optimal
antibody concentration. In addition, we added a PE-labeled
mouse IgG1-antibody (Coulter Beckman) to a second anti-CD45
stained blood sample as the isotype control. Subsequent lysis was
done with ammonium chloride, and at least 200.000 CD45+ cells
were acquired. Two blinded investigators independently assessed
the number of HSCs. Day-to-day variability of the absolute HSC
number was below 12% as assessed by flow cytometry of HSCs in
8 subjects on 4 consecutive days. Inter-assay variability (n=10)
was below 5%.
Statistical analysis
Statistical analysis was performed with Statistical Package for
the Social Sciences (SPSS) 15.0 for Windows and GraphPad Prism
software (GraphPad Prism Software Inc. San Diego, California,
USA). Two-sided p-values ,0.05 were considered statistically
significant for all statistical procedures. Normally distributed
continuous variables are expressed as mean 6 SEM. All variables
used for parametric statistical analyses were analyzed for normal
distribution using Kolmogorov-Smirnov test. In case of non-
normal distribution parameters are displayed as median [inter-
quartile range]. Follow-up time is displayed as median [min–max].
Univariate comparisons of continuous variables between groups
were performed using an unpaired t test or the nonparametric
Wilcoxon rank sum test in case of non-normally distributed
variables. Dichotomized variables were compared using Pearson’s
x2-test. Univariate correlation analysis was performed by
Spearman correlation analysis. In addition, parameters indepen-
dently associated with incident CVE were identified by univariate
and multivariate Cox proportional hazards models. Variables
found to be statistically significant at a 10% level in the univariate
analysis were included in the multivariate model using backward
elimination. The distribution of the time-to-event variables were
estimated using the Kaplan-Meier method with log-rank testing.
Receiver operator characteristics (ROC) procedures were used to
identify optimal cut-off values.
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